Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 16/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | GSK3A | P49840 | 10/20 | 0.69 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.53 |
| ▸ | CLK2 | P49760 | 1/20 | 0.48 |
| ▸ | CLK3 | P49761 | 1/20 | 0.48 |
| ▸ | CDK7 | P50613 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5390676 | 0.89 | GSK3B (0.69) | GSK3BGSK3ADYRK1AMAP4K4CDK1 | |
| SCHEMBL7155632 | 0.83 | GSK3B (0.62) | GSK3BGSK3ADYRK1AMAP4K4CDK1 | |
| SCHEMBL31060518 | 0.82 | GSK3B (1.00) | GSK3BCYP1A2 | |
| SCHEMBL6489919 | 0.82 | GSK3B (1.00) | GSK3BCYP1A2 | |
| SCHEMBL30746807 | 0.81 | GSK3B (1.00) | GSK3BCYP1A2GSK3ADYRK1ACDK2 | |
| SCHEMBL31221867 | 0.81 | CDK7 (0.72) | GSK3BGSK3ADYRK1AMAP4K4CDK1 | |
| SCHEMBL7261966 | 0.81 | GSK3B (0.61) | GSK3BCYP1A2GSK3ADYRK1AMAP4K4 | |
| SCHEMBL4297488 | 0.80 | GSK3B (0.62) | GSK3BCYP1A2GSK3ADYRK1A | |
| SCHEMBL10059340 | 0.79 | GSK3B (0.69) | GSK3BGSK3ADYRK1AMAP4K4CDK1 | |
| SCHEMBL11233493 | 0.78 | GSK3B (0.58) | GSK3BCYP1A2GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297792-B2 | Pyrazolopyridines and pyrazolopyridazines as antidiabetics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-20 | — | — | US | disclosed |
| US-20060223800-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES ADN ANTIDIABETICS | GARLAND STEPHEN | 2006-10-05 | — | — | US | disclosed |
| US-7109199-B2 | Pyrazolopyridines and pyrazolopyridazines as antidiabetics | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-01-29 | — | — | US | disclosed |
| EP-1319001-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024694-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM, P.L.C. (GB) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223800-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES ADN ANTIDIABETICS | ADK, PDXK, GPR119 | GSK3B 1358/4885CYP1A2 127/4885GSK3A 1785/4885 |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | PDXK, GCK, IAPP | GSK3B 2526/4885CYP1A2 95/4885GSK3A 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.